NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AffaMed Therapeutics

AffaMed Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://affamed.com/

Last Round

Series B

Mar 30, 2021

Total Funding Raised

$250M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AffaMed Therapeutics is a biopharmaceutical company that develops and commercializes transformative pharmaceutical products for ophthalmic, neurological, and psychiatric disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Mental Health

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

ophthalmologybiopharmaceuticalclinical stage pharmabiotechdrug developmentin-licensingmedical devicesmedtechChina healthcare marketophthalmic therapiesintraocular lensesIOLsbiologicsneurological disordersdigital therapeuticsDTxpsychiatric disordersAI therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AffaMed Therapeutics Comparables

Compare AffaMed Therapeutics with similar companies based on industry and business-model similarity.

AffaMed Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Arctic Vision
88%
Allgenesis Biotherapeutics Inc.
80%
Ocumension Therapeutics
78%

AffaMed Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 30, 2021
Series AFeb 1, 2019

AffaMed Therapeutics Investors

Notable investors and investment history

AffaMed Therapeutics investors
InvestorRounds
Lake Bleu CapitalSeries B
CBC GroupSeries B, Series A
Superstring Capital ManagementSeries B
Fountainhead PartnersSeries B
Partners InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased from 0 to 8, representing 25% of headcount.

  • Jun 21, 2026

    Monthly visitors increased 30% MoM.

AffaMed Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AffaMed Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AffaMed Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range32
Year Founded2019
Last FundingMar 30, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.